Lloyd-Smith Malcolm
- SEC CIK
- 0001557146
No open-market purchases or sales filed in the past year.
Current role at each company
- NBIX Neurocrine Biosciences IncChief Integration Officeras of Feb 8, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Lloyd-Smith Malcolm as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2021 (view filing) | Jul 27 | 2 days | Lloyd-Smith MalcolmChief Regulatory Officer | SSale | −16.7K | $93.80 | −$1.57M | −51.4%15.8K after | |
| Feb 9, 2022 (view filing) | Feb 7-8 | 2 days | Lloyd-Smith MalcolmChief Regulatory Officer | SSale | −3.38K | $80.48 | −$272.2K | −15.3%18.7K after | 4 lots |
| Aug 16, 2022 (view filing) | Aug 12 | 4 days | Lloyd-Smith MalcolmChief Regulatory Officer | SSale | −21.5K | $105.95 | −$2.28M | −53.3%18.9K after | |
| Feb 2, 2023 (view filing) | Jan 31 | 2 days | Lloyd-Smith MalcolmChief Integration Officer | SSale | −1.67K | $110.02 | −$183.3K | −5.5%28.6K after | |
| Feb 8, 2023 (view filing) | Feb 6-8 | 2 days | Lloyd-Smith MalcolmChief Integration Officer | SSale | −15.3K | $102.64 | −$1.57M | −26.6%42.3K after | 4 lots |